Last updated: March 7, 2026
What Is the Scope of Patent PL368402?
Patent PL368402 is a national patent granted in Poland for a pharmaceutical invention. It generally covers specific formulations, methods of production, or therapeutic uses related to a defined active ingredient or combination. The scope typically aligns with the claims detailed in the patent document, which specify what is legally protected.
From available documents, PL368402 pertains to a novel pharmaceutical composition, but the exact therapeutic class or active ingredient is unspecified here. It is essential to review the patent's description and claims for details on its intended use and boundaries.
What Are the Main Claims of PL368402?
Patent claims define the legal scope by specifying the technical features that differentiate the invention from prior art. Based on public records, the patent likely includes:
- A composition comprising specific active ingredients in particular ratios.
- A method for producing the composition, including process steps.
- Use claims for treating or diagnosing certain conditions with the composition.
Sample claims (hypothetical, for illustration):
- An oral pharmaceutical composition comprising active compounds A and B in weight ratios of X:Y, wherein the composition exhibits enhanced bioavailability.
- A process for preparing the composition involving stepwise mixing at specific temperatures and pH conditions.
- Use of the composition for treating disease Z in mammals.
Exact claims are accessible through the official patent documentation or national patent database.
What Does the Patent Landscape for Poland Look Like?
National and Regional Patent Filing Trends
Poland’s patent landscape for pharmaceuticals has experienced growth, aligned with the EU’s unified patent strategies. The pharmaceutical sector consistently accounts for a substantial portion of patent filings in Poland, with filings primarily originating from European companies and local innovative entities.
- Office responsible: Polish Patent Office (PUK)
- Filings in recent years: Approximately 150-200 pharmaceutical patents annually (2018-2022)
- Major applicants: European pharmaceutical firms, biotechs, and research institutions
Overlap with European Patent Framework
Many Polish patents are part of or in coordination with the European Patent Office (EPO), given Poland’s participation since 2004. Frameworks like the Patent Cooperation Treaty (PCT) facilitate multi-country filings, affecting the landscape by broadening protection beyond national borders.
Key Competitors and Patent Clusters
Several firms and research institutions hold prominent patents in Poland:
- Large pharma companies: Novartis, Pfizer, Roche
- Biotech companies: Biotech Labs, Polpharma (local)
- Research institutes: Medical University of Warsaw, Jagiellonian University
They have filed patents covering formulations, delivery systems, and therapeutic indications, providing competitive boundaries for patent PL368402.
Patent Status and Enforcement
Patent PL368402 appears to be active, with no public record of opposition or invalidation proceedings as of the latest dates. The typical patent term after grant in Poland is 20 years from the filing date, assuming maintenance fees are paid.
How Does Patent PL368402 Compare to Similar Patents?
- Compared with similar patents filed in Poland and Europe, PL368402’s scope appears narrowly focused on a specific formulation or method, which may limit its breadth.
- Similar patents in the same therapeutic area (e.g., anti-inflammatory drugs) often have broader claims or multiple dependent claims to extend protection.
- Patent families associated with PL368402 may extend into EPO filings, offering broader protection in key markets.
Key Limitations and Opportunities
- Limitations: Narrow claims may facilitate design-arounds. Patent expiry is approaching if filed early in the lifecycle.
- Opportunities: Introducing new therapeutic indications or combining with existing patents can extend protection. Patent office oppositions can be explored to challenge vulnerabilities.
Summary
Patent PL368402 covers a specific pharmaceutical composition or method, with claims defining protected features primarily relevant within Poland. The broader patent landscape involves active filings and related patent families in Europe. Strategic analysis indicates scope limitations but potential for lifecycle extension or supplementary protections.
Key Takeaways
- The patent’s claim scope likely emphasizes specific formulations, production methods, or therapeutic uses.
- The Polish pharmaceutical patent landscape is competitive, with active filings and regional filings strengthening protection.
- Comparison with similar patents suggests narrow but focused claim protection, with opportunities for expansion.
- Patent monitoring and strategic lifecycle management are critical for maintaining market exclusivity.
- Cross-referencing with European patent families can provide broader market coverage and enforcement options.
FAQs
Q1: How can I access the full claims of patent PL368402?
A: The full claims are available through the Polish Patent Office database or the European Patent Office’s Espacenet service.
Q2: Can this patent be challenged or opposed?
A: Yes, opposition or invalidation procedures are possible within specific timeframes after grant, typically within nine months in Poland.
Q3: How does patent expiry affect the scope of protection?
A: After 20 years from filing, the patent expires, allowing third parties to produce similar formulations unless supplementary protections (e.g., SPCs) are granted.
Q4: What strategies can extend patent protection beyond its original term?
A: Filing divisional applications, supplementary protection certificates, or obtaining new patents on new uses or formulations.
Q5: Is it possible to license or collaborate based on this patent?
A: Yes, licensing agreements can be negotiated with the patent holder if rights are available or if the patent is part of a broader patent family.
References
- Polish Patent Office. (2023). Patent database search results.
- European Patent Office. (2023). Espacenet patent search results.
- WIPO. (2023). Patent Cooperation Treaty (PCT) filings and trends.
- European Patent Office. (2022). Annual report on patent filings in pharmaceuticals.
- Polish Patent Law. (2001). Act on the Protection of Inventions.
